CTSL and cancer: Interestingly, Ueki et al. slightly maneuvered this approach to acquire a prodrug which gets serially activated by histone deacetylase (HDAC) and cathepsin L, and subsequently delivers the cytotoxic payload, puromycin, to cancer cells [184].